Email updates

Keep up to date with the latest news and content from JBDC and BioMed Central.

Open Access Focus

Nomen est Omen: do antidepressants increase p11 or S100A10?

Hari Manev* and Radmila Manev

Author Affiliations

The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago. Chicago, Illinois 60612, USA

For all author emails, please log on.

Journal of Biomedical Discovery and Collaboration 2006, 1:5  doi:10.1186/1747-5333-1-5

Published: 13 April 2006

Abstract

Occasionally, multiple names are given to the same gene/protein. When this happens, different names can be used in subsequent publications, for example in different research areas, sometimes with little or no awareness that the same entity known under a different name may have a major role in another field of science. Recent reports about the protein p11 presented findings that this protein, commonly known as S100A10, may play a crucial role in depression and antidepressant treatment mechanisms. One set of data showed an increased expression of this protein in the brain of mice treated with antidepressants. P11/S100A10 is only one of several S100 proteins expressed in the brain. Interestingly, it has been previously noted that antidepressant treatment increases the brain content of another S100 protein, S100B. It appears that up-regulating the brain content of various S100 proteins might be a common feature of antidepressants. In cells coexpressing S100A10 and S100B, these proteins may interact and exert opposite regulatory roles. Nevertheless, S100A10 is predominantly expressed in certain types of neurons whereas S100B is more abundant in glia. Thus, an interplay among multiple members of the S100 proteins might be important in determining the region and cell specificity of antidepressant mechanisms. Calling the p11 protein by its other name, S100A10, may prompt more investigators from different fields to participate in this new direction of neurobiological research.